JP7286675B2 - Ｆｇｆｒ３関連軟骨異形成症の処置のための方法及び医薬組成物 - Google Patents

Ｆｇｆｒ３関連軟骨異形成症の処置のための方法及び医薬組成物 Download PDF

Info

Publication number
JP7286675B2
JP7286675B2 JP2020560576A JP2020560576A JP7286675B2 JP 7286675 B2 JP7286675 B2 JP 7286675B2 JP 2020560576 A JP2020560576 A JP 2020560576A JP 2020560576 A JP2020560576 A JP 2020560576A JP 7286675 B2 JP7286675 B2 JP 7286675B2
Authority
JP
Japan
Prior art keywords
fgfr3
epicatechin
treatment
mutant
chondrodysplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511379A5 (https=
JP2021511379A (ja
JPWO2019145356A5 (https=
Inventor
ルジェ－マル，ロランス
セグラ・カレテーロ，アントニオ
カディス・グレア，マリア・デ・ラ・ルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Assistance Publique Hopitaux de Paris APHP
Fondation Imagine
Universite Paris Cite
Original Assignee
Universidad de Granada
Assistance Publique Hopitaux de Paris APHP
Fondation Imagine
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada, Assistance Publique Hopitaux de Paris APHP, Fondation Imagine, Universite Paris Cite filed Critical Universidad de Granada
Publication of JP2021511379A publication Critical patent/JP2021511379A/ja
Publication of JP2021511379A5 publication Critical patent/JP2021511379A5/ja
Publication of JPWO2019145356A5 publication Critical patent/JPWO2019145356A5/ja
Application granted granted Critical
Publication of JP7286675B2 publication Critical patent/JP7286675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2020560576A 2018-01-24 2019-01-23 Ｆｇｆｒ３関連軟骨異形成症の処置のための方法及び医薬組成物 Active JP7286675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305053 2018-01-24
EP18305053.3 2018-01-24
PCT/EP2019/051622 WO2019145356A1 (en) 2018-01-24 2019-01-23 Methods and pharmaceutical compositions for the treatment of fgfr3-related chondrodysplasias

Publications (4)

Publication Number Publication Date
JP2021511379A JP2021511379A (ja) 2021-05-06
JP2021511379A5 JP2021511379A5 (https=) 2022-01-17
JPWO2019145356A5 JPWO2019145356A5 (https=) 2022-01-17
JP7286675B2 true JP7286675B2 (ja) 2023-06-05

Family

ID=61163620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560576A Active JP7286675B2 (ja) 2018-01-24 2019-01-23 Ｆｇｆｒ３関連軟骨異形成症の処置のための方法及び医薬組成物

Country Status (5)

Country Link
US (2) US11951090B2 (https=)
EP (1) EP3743062B1 (https=)
JP (1) JP7286675B2 (https=)
ES (1) ES2985639T3 (https=)
WO (1) WO2019145356A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250041262A1 (en) * 2021-12-16 2025-02-06 Institut National de la Santé et de la Recherche Médicale Compositions for the treatment of fgfr3-related cognitive deficits with a catechin
US20250041263A1 (en) * 2021-12-20 2025-02-06 Institut National de la Santé et de la Recherche Médicale Use of catechin for the treatment of fgfr-related bone repair and bone formation impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046375A1 (en) 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046375A1 (en) 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Food & Nutrition Research，2015年，Vol. 59, 29311，pp. 1-10

Also Published As

Publication number Publication date
ES2985639T3 (es) 2024-11-06
US20210052546A1 (en) 2021-02-25
EP3743062B1 (en) 2024-07-17
US11951090B2 (en) 2024-04-09
JP2021511379A (ja) 2021-05-06
EP3743062C0 (en) 2024-07-17
US20230414561A1 (en) 2023-12-28
WO2019145356A1 (en) 2019-08-01
EP3743062A1 (en) 2020-12-02
US12257232B2 (en) 2025-03-25

Similar Documents

Publication Publication Date Title
Jang et al. Coffee consumption promotes skeletal muscle hypertrophy and myoblast differentiation
EP2983694B1 (en) Compositions for rejuvenating skeletal muscle stem cells
EP2945622B1 (en) Composition comprising urolithin b and testosterone, leucine and/or creatine for muscle growth
US12257232B2 (en) Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias
EP3132692A1 (en) Compositions comprising small molecular inhibitors suitable to inhibit and stimulate signaling pathways in a manner leading to prevention of muscle atrophy
JP2020519688A (ja) 抗糖尿病活性および他の有用な活性を有する植物抽出物
EP3054942B1 (en) Treatments for proliferative vitreoretinopathy
KR102880608B1 (ko) 크릴새우 추출물을 포함하는 근육 질환의 예방 또는 치료용 약학 조성물
CN111356468B (zh) 包含黄漆木提取物作为有效成分的用于预防或治疗纤维化疾病的组合物
JPWO2018199287A1 (ja) クリスタリン網膜症の処置および／または予防方法
JP6553375B2 (ja) Ｕｃｐ−１発現促進剤
Martín-González et al. A novel dietary multifunctional ingredient reduces body weight and improves leptin sensitivity in cafeteria diet-fed rats
JP7023518B2 (ja) 分泌障害の処置のための方法および組成物
KR101840092B1 (ko) 에틸 파이루베이트(ethyl pyruvate)를 포함하는 말초신경계 퇴행성 질환의 예방 또는 치료용 약학적 조성물
WO2015160181A1 (ko) 황칠 추출물을 포함하는 혈관 평활근세포 이상 증식 및 이동성 질환 또는 혈관 내막증식 질환의 예방 또는 치료용 조성물
JP2025525540A (ja) ホモ多糖類またはその誘導体を含む組成物、およびそれを用いて骨量減少を予防および／または治療するための方法
KR102432016B1 (ko) 신경염증질환 예방 또는 치료용 조성물
KR20190125068A (ko) 6'-o-아세틸 만지페린을 포함하는 비만 또는 비만 관련 질환의 예방 또는 개선용 조성물
KR102022120B1 (ko) 델피니딘 및 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물
KR101404185B1 (ko) Ｗｎｔ／β-카테닌 신호전달계와 관련된 질병의 예방 및 치료용 약학 조성물
JP7333626B2 (ja) アルツハイマー型認知症予防・治療用組成物、アミロイドβオリゴマー神経毒性低減用組成物
WO2011111355A1 (ja) Ｌ－セリンを含有する末梢神経障害の予防・治療剤
mi Kim et al. Therapeutic potential of a Novel Peptide, Myoki, in Muscle Atrophy: Mechanisms and applications
EP4000622A1 (en) Pharmaceutical composition for preventing or treating bone diseases
Li et al. Zeaxanthin Exhibits Protective Effects in Myocardial Injury by Inhibiting TGF-β/Smad2/3 and p38MAPK/NF-κB Signaling Pathways

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230524

R150 Certificate of patent or registration of utility model

Ref document number: 7286675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150